[
  {
    "ts": null,
    "headline": "H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its […]",
    "url": "https://finnhub.io/api/news?id=21a97619abd38bf4e6e049d8f55abb2b40db7d843ccca1517263d64d443fad16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761668642,
      "headline": "H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)",
      "id": 137243774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its […]",
      "url": "https://finnhub.io/api/news?id=21a97619abd38bf4e6e049d8f55abb2b40db7d843ccca1517263d64d443fad16"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate",
    "summary": "Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares oscillate lately, drawing more than a few glances from investors deciding whether to get in, stay in, or head for the exits. The last close landed at $420.17, with the stock posting an 8.9% gain over the past 30 days. This has been a solid rebound after a slower patch that saw shares down 1.4% this week and 10.7% over the past year. Looking further back, the story turns...",
    "url": "https://finnhub.io/api/news?id=772d5e98355f402f9d2a4a6292d5c961db5f7023b21a816792e7c413cb590962",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761667718,
      "headline": "Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate",
      "id": 137243775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares oscillate lately, drawing more than a few glances from investors deciding whether to get in, stay in, or head for the exits. The last close landed at $420.17, with the stock posting an 8.9% gain over the past 30 days. This has been a solid rebound after a slower patch that saw shares down 1.4% this week and 10.7% over the past year. Looking further back, the story turns...",
      "url": "https://finnhub.io/api/news?id=772d5e98355f402f9d2a4a6292d5c961db5f7023b21a816792e7c413cb590962"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
    "summary": "Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.",
    "url": "https://finnhub.io/api/news?id=fba6d3fdc60910273af1e828bb1eac11feb8cc183f7a292061cb9d82cd7a94d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761666720,
      "headline": "Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
      "id": 137243776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.",
      "url": "https://finnhub.io/api/news?id=fba6d3fdc60910273af1e828bb1eac11feb8cc183f7a292061cb9d82cd7a94d9"
    }
  },
  {
    "ts": null,
    "headline": "Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know",
    "summary": "Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=1c6c8b50fc047f1bfe4cfa18e4b8780127a8658e675aa71d13466ead0e6f3a91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660019,
      "headline": "Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know",
      "id": 137243777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=1c6c8b50fc047f1bfe4cfa18e4b8780127a8658e675aa71d13466ead0e6f3a91"
    }
  },
  {
    "ts": null,
    "headline": "If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These",
    "summary": "These two have been neglected by Wall Street too much.",
    "url": "https://finnhub.io/api/news?id=3f4877bc55c857a746298ac942a098b8885005ccb902af51d6014e32948f2e16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761659580,
      "headline": "If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These",
      "id": 137238011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "These two have been neglected by Wall Street too much.",
      "url": "https://finnhub.io/api/news?id=3f4877bc55c857a746298ac942a098b8885005ccb902af51d6014e32948f2e16"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings",
    "summary": "Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions. Learn more about VRTX stock here.",
    "url": "https://finnhub.io/api/news?id=f7f84069d5333141bcb00d1a145393925dd185cb0c59c7be06da5aff41ab17af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652773,
      "headline": "Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings",
      "id": 137239695,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962527/image_1386962527.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions. Learn more about VRTX stock here.",
      "url": "https://finnhub.io/api/news?id=f7f84069d5333141bcb00d1a145393925dd185cb0c59c7be06da5aff41ab17af"
    }
  }
]